AI assistant
Arcus Biosciences, Inc. — Director's Dealing 2021
Jun 7, 2021
31966_dirs_2021-06-07_08090333-3c2c-44cc-b8de-26671df48f33.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2021-06-03
Reporting Person: Machado Patrick (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-03 | Common Stock | A | 3000 | $0.00 | Acquired | 6000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-03 | Stock Option (Right to Buy) | $24.79 | A | 14100 | Acquired | 2031-06-02 | Common Stock (14100) | Direct |
Footnotes
F1: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021.
F3: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.